Nicholas J. Talley, MD, PhD
What are the efficacy and safety of quadruple-drug therapy compared with standard triple-drug therapy for eradicating Helicobacter pylori infection?
Randomized controlled trial. ClinicalTrials.gov NCT00669955.
39 centers in France, Germany, Ireland, Italy, Poland, Spain, and the UK.
440 patients ≥ 18 years of age (mean age 48 y, 54% men among 438 patients treated) with confirmed H. pylori infection (positive urea breath test; positive rapid urease test; and positive histology, culture, or polymerase chain reaction assay) and upper gastrointestinal (GI) symptoms. Women of child-bearing potential had to use medically acceptable contraception during and up to 30 days after the end of the study. Exclusion criteria included substantial organ impairment; severe or unstable cardiopulmonary or endocrine disease; history of upper GI tract surgery; bleeding or iron-deficiency anemia; Barrett esophagus or high-grade dysplasia; dysphagia; history of cancer; drug or alcohol misuse in the past year; past use of antibiotics for H. pylori; continuous use of antiulcer drugs, antibiotics or bismuth compounds, systemic glucocorticoids, nonsteroidal antiinflammatory drugs, or anticoagulation or platelet aggregation inhibitors other than acetylsalicylic acid ≤ 100 mg/d; and pregnancy or nursing.
Quadruple therapy for 10 days (n = 218) or standard therapy for 7 days (n = 222). Quadruple therapy comprised omeprazole, 20 mg, twice daily, plus 3 capsules 4 times daily; each capsule contained a combination of bismuth subcitrate potassium, 140 mg; metronidazole, 125 mg; and tetracycline hydrochloride, 125 mg. Standard therapy comprised omeprazole, 20 mg; amoxicillin, 500 mg; and clarithromycin, 500 mg, each twice daily.
H. pylori eradication (negative urea breath tests at 6 and 10 wk) and adverse events.
91% completed the study (intention-to-treat analysis).
Quadruple therapy was better than standard therapy for eradicating H. pylori (Table). The proportion of patients with treatment-emergent adverse events was similar in both groups (all events 47% vs 51%, P = 0.44; severe events 5% vs 7%, P = 0.36; P values calculated from data in article).
Quadruple-drug therapy was better than standard triple-drug therapy for eradicating H. pylori in adults.
Quadruple-drug therapy vs standard triple-drug therapy in adults with H. pylori infection†
†Abbreviations defined in Glossary. RBI, NNT, and CI calculated from data in article.
Nicholas J. Talley. Quadruple-drug therapy was better than triple-drug therapy for eradicating Helicobacter pylori in adults. Ann Intern Med. 2011;154:JC6–2. doi: 10.7326/0003-4819-154-12-201106210-02002
Download citation file:
Published: Ann Intern Med. 2011;154(12):JC6-2.
Gastroenterology/Hepatology, H. Pylori, Infectious Disease, Peptic Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use